Takeda Pharmaceutical
TAK | NYSE
$21.59
+$0.16 (+0.75%)
At close: Nov 16, 2026, 4:00 PM ET
$21.86
+$0.27 (+1.25%)
After-hours:
Nov 16, 2026, 7:23 PM ET
Takeda Pharmaceutical Company Profile
Company profile explainedCompany Profile
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
Key Executives
| Name | Position |
|---|---|
| Julie Kim | CEO, President & Director |
| Michael Fox | Chief Operating Officer |
| Milano Furuta | Chief Financial Officer & Director |
| Andrew S. Plump | President of Research & Development and Representative Director |
| Gabriele Ricci | Chief Data & Technology Officer |
| Haruhiko Hirate | Member of Management Board |
| Iwaaki Taniguchi | Senior Vice President of Corporate Finance & Controlling Department |
| Norimasa Takeda | Chief Accounting Officer & Corporate Controller |
| Salvatore Alesci | Member of Management Board and Head of R&D Global Science & Biomedical Policy |
| Seigo Izumo | Chair of Management Board |
Takeda Pharmaceutical
| Country | Japan |
| IPO Date | Jan 5, 2010 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 47,029 |
| CEO | Julie So-Young Kim |
Contact Details
1-1, Nihonbashi-Honcho 2-chome Tokyo,
OS 103-8668 Japan
Stock Details
| Ticker Symbol | TAK |
| Exchange | NYSE |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001395064 |
| CUSIP Number | 874060205 |
| ISIN Number | US8740602052 |
| SIC Code | 2834 |
Recent News
- 4 days ago / reuters.comTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
- 4 days ago / businesswire.comTakeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States
- 13 days ago / 247wallst.comMost Investors Own VEA. Few Know About This International Cash Cows ETF
- 18 days ago / seekingalpha.comTakeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash Flow
- 18 days ago / marketbeat.comWhat Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
- 19 days ago / benzinga.comTakeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
- 19 days ago / seekingalpha.comTakeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
- 19 days ago / businesswire.comTakeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
- 25 days ago / businesswire.comTakeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
- 29 days ago / businesswire.comFirst and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
Add to Watchlist
Select watchlists to add or remove TAK